WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets ...
Proteomic aging clocks are moving into clinical trials, but FDA surrogate endpoint standards and assay reproducibility gaps ...
Heart failure Phase IV studies use digital tools and remote monitoring to reduce patient dropout when perceived personal ...
FDA grants priority review to BridgeBio's oral infigratinib for pediatric achondroplasia, offering a once-daily pill ...
Zenas BioPharma releases Phase 3 obexelimab IgG4-related disease data with open-label extension results showing durability ...
When scan sets split into separate rows, MCAs lose the parent schedule. Here is what that costs you and how to fix it.
FDA flagged four patient deaths in evenamide's schizophrenia trial. The question isn't the drug, it's why real-time ...
TRIUMPH-2's Phase 3 data on retatrutide in 1,152 T2D patients challenges every assumption sponsors hold about GLP-1 trial ...
WCG's Activation Intelligence cuts study activation time by 20 hours per trial by reconciling conflicting information across ...
GCCL and LabConnect sign MOU to streamline cross-regional clinical trial support across North America and Asia-Pacific ...
AKIR001 radiopharmaceutical shows no dose-limiting toxicities in eight patients, with imaging confirming selective tumor ...
ArkBio receives FDA clearance for AK0406, a drug-Fc conjugate designed to prevent influenza in adults during the upcoming U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results